Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan L Steinberg

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Journal of Pediatric Urology|February 2, 2020
Neurogenic bladder monitoring using the cystomanometer and cystoelastometerChristopher S Cooper, Ryan L Steinberg, Lewis J Thomas, et al.
BJU International|March 21, 2025
Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter?Ian M McElree, Grant M Henning, Ryan L Steinberg, et al.
The Journal of Urology|July 13, 2022
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder CancerIan M McElree, Vignesh T Packiam, Ryan L Steinberg, et al.
Urologic Oncology|May 25, 2025
Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostateAlexander C Martin, Ian M McElree, Sarah L Mott, et al.
Cancers|January 8, 2025
Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial CarcinomaIan M McElree, Vignesh T Packiam, Ryan L Steinberg, et al.
Cancers|July 27, 2024
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder TumorIan M McElree, Vignesh T Packiam, Ryan L Steinberg, et al.
Urolithiasis|September 29, 2025
Variants of unknown significance are common in brushite stone formers undergoing genetic testing for nephrolithiasisTomas Paneque, Kyle Berst, Meenakshi Sambharia, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|September 1, 2021
Clinical and radiographic outcomes following salvage intervention for ureteropelvic junction obstructionJoseph J Crivelli, Brett A Johnson, Ryan L Steinberg, et al.
The Journal of Urology|July 27, 2022
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder CancerIan M McElree, Ryan L Steinberg, Alex C Martin, et al.
Infection Control and Hospital Epidemiology|November 7, 2024
A pilot intervention trial to reduce the use of post-procedural antimicrobials after common endourologic surgeriesDaniel J Livorsi, Vignesh T Packiam, Qianyi Shi, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Journal of Pediatric Urology|February 2, 2020
Neurogenic bladder monitoring using the cystomanometer and cystoelastometerChristopher S Cooper, Ryan L Steinberg, Lewis J Thomas, et al.
BJU International|March 21, 2025
Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter?Ian M McElree, Grant M Henning, Ryan L Steinberg, et al.
The Journal of Urology|July 13, 2022
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder CancerIan M McElree, Vignesh T Packiam, Ryan L Steinberg, et al.
Urologic Oncology|May 25, 2025
Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostateAlexander C Martin, Ian M McElree, Sarah L Mott, et al.
Cancers|January 8, 2025
Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial CarcinomaIan M McElree, Vignesh T Packiam, Ryan L Steinberg, et al.
Cancers|July 27, 2024
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder TumorIan M McElree, Vignesh T Packiam, Ryan L Steinberg, et al.
Urolithiasis|September 29, 2025
Variants of unknown significance are common in brushite stone formers undergoing genetic testing for nephrolithiasisTomas Paneque, Kyle Berst, Meenakshi Sambharia, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|September 1, 2021
Clinical and radiographic outcomes following salvage intervention for ureteropelvic junction obstructionJoseph J Crivelli, Brett A Johnson, Ryan L Steinberg, et al.
The Journal of Urology|July 27, 2022
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder CancerIan M McElree, Ryan L Steinberg, Alex C Martin, et al.
Infection Control and Hospital Epidemiology|November 7, 2024
A pilot intervention trial to reduce the use of post-procedural antimicrobials after common endourologic surgeriesDaniel J Livorsi, Vignesh T Packiam, Qianyi Shi, et al.
Pageof 8